Compare Stocks: ALLR, GANX, RLYB, and SERA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLR Allarity Therapeutics	$1.37 +0.7%	$1.31	$0.77 ▼ $2.35	$21.80M	0.51	72,726 shs	45,504 shs
GANX Gain Therapeutics	$2.12 -1.9%	$1.81	$1.51 ▼ $4.34	$92.53M	0.19	527,465 shs	517,606 shs
RLYB Rallybio	$16.99 +0.2%	$16.09	$3.67 ▼ $17.57	$90.23M	-0.9	29,170 shs	12,921 shs
SERA Sera Prognostics	$1.96 -2.5%	$1.99	$1.56 ▼ $3.95	$76.75M	0.96	39,618 shs	13,526 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLR Allarity Therapeutics	0.00%	-1.44%	+17.09%	+1.48%	+37.01%
GANX Gain Therapeutics	0.00%	+16.48%	+27.71%	+21.14%	+36.77%
RLYB Rallybio	0.00%	+5.14%	+6.45%	+18.81%	+296.67%
SERA Sera Prognostics	0.00%	-5.31%	-10.91%	+13.95%	-14.78%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLR Allarity Therapeutics	$1.37 +0.7%	$1.31	$0.77 ▼ $2.35	$21.80M	0.51	72,726 shs	45,504 shs
GANX Gain Therapeutics	$2.12 -1.9%	$1.81	$1.51 ▼ $4.34	$92.53M	0.19	527,465 shs	517,606 shs
RLYB Rallybio	$16.99 +0.2%	$16.09	$3.67 ▼ $17.57	$90.23M	-0.9	29,170 shs	12,921 shs
SERA Sera Prognostics	$1.96 -2.5%	$1.99	$1.56 ▼ $3.95	$76.75M	0.96	39,618 shs	13,526 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLR Allarity Therapeutics	0.00%	-1.44%	+17.09%	+1.48%	+37.01%
GANX Gain Therapeutics	0.00%	+16.48%	+27.71%	+21.14%	+36.77%
RLYB Rallybio	0.00%	+5.14%	+6.45%	+18.81%	+296.67%
SERA Sera Prognostics	0.00%	-5.31%	-10.91%	+13.95%	-14.78%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLR Allarity Therapeutics	2.00	Hold	$10.25	648.18% Upside
GANX Gain Therapeutics	2.67	Moderate Buy	$7.50	253.77% Upside
RLYB Rallybio	1.00	Sell	N/A	N/A
SERA Sera Prognostics	2.67	Moderate Buy	$5.50	180.61% Upside

Current Analyst Ratings Breakdown

Latest ALLR, GANX, RLYB, and SERA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	GANX Gain Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
8/5/2026	RLYB Rallybio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/31/2026	SERA Sera Prognostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	ALLR Allarity Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/16/2026	SERA Sera Prognostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/1/2026	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
6/30/2026	GANX Gain Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
6/17/2026	SERA Sera Prognostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/9/2026	GANX Gain Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/8/2026	ALLR Allarity Therapeutics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$9.75 ➝ $10.25
6/4/2026	SERA Sera Prognostics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.00

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLR Allarity Therapeutics	$345K	63.18	N/A	N/A	$0.61 per share	2.25
GANX Gain Therapeutics	$50K	1,850.34	N/A	N/A	$0.26 per share	8.15
RLYB Rallybio	$646K	139.68	N/A	N/A	$17.79 per share	0.96
SERA Sera Prognostics	$80K	959.42	N/A	N/A	$1.52 per share	1.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLR Allarity Therapeutics	-$11.23M	-$0.78	N/A	N/A	N/A	N/A	-109.94%	-47.27%	N/A
GANX Gain Therapeutics	-$20.16M	-$0.50	N/A	N/A	N/A	N/A	-161.59%	-118.36%	N/A
RLYB Rallybio	-$8.98M	-$4.34	N/A	N/A	N/A	-911.07%	-40.53%	-38.13%	N/A
SERA Sera Prognostics	-$31.93M	-$0.67	N/A	N/A	N/A	-47,475.72%	-46.71%	-34.06%	N/A

Latest ALLR, GANX, RLYB, and SERA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ALLR Allarity Therapeutics	-$0.25	-$0.21	+$0.04	-$0.21	N/A	N/A
8/12/2026	Q2 2026	SERA Sera Prognostics	-$0.1542	-$0.18	-$0.0258	-$0.18	$0.07 million	$0.03 million
8/11/2026	Q2 2026	GANX Gain Therapeutics	-$0.1380	-$0.11	+$0.0280	-$0.11	$0.03 million	N/A
8/6/2026	Q2 2026	RLYB Rallybio	-$1.28	-$1.09	+$0.19	$7.53	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	N/A
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A
RLYB Rallybio	N/A	N/A	N/A	N/A	N/A
SERA Sera Prognostics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLR Allarity Therapeutics	N/A	1.23	1.23
GANX Gain Therapeutics	0.02	4.36	4.69
RLYB Rallybio	N/A	27.26	27.26
SERA Sera Prognostics	N/A	1.98	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLR Allarity Therapeutics	11.53%
GANX Gain Therapeutics	11.97%
RLYB Rallybio	90.34%
SERA Sera Prognostics	54.64%

Insider Ownership

Company	Insider Ownership
ALLR Allarity Therapeutics	0.16%
GANX Gain Therapeutics	4.15%
RLYB Rallybio	10.30%
SERA Sera Prognostics	11.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLR Allarity Therapeutics	10	15.91 million	15.89 million	Not Optionable
GANX Gain Therapeutics	20	43.64 million	41.83 million	Optionable
RLYB Rallybio	40	5.31 million	4.76 million	Not Optionable
SERA Sera Prognostics	120	39.16 million	34.73 million	Optionable

ALLR, GANX, RLYB, and SERA Headlines

Recent News About These Companies

Sera Prognostics, Inc. Q2 2026 Earnings Call Summary

August 14 at 7:38 PM | finance.yahoo.com

Sera Prognostics, Inc.: Sera Prognostics Reports Second Quarter 2026 Financial Results

August 13 at 9:38 AM | finanznachrichten.de

Sera Prognostics Hits Key Milestones in Second Quarter 2026: Expanding Commercial Engagements and Unlocking Policy Momentum

August 12, 2026 | news.themarketisopen.comN

Sera Prognostics Q2 Earnings Call Highlights

August 12, 2026 | marketbeat.com

Sera Prognostics, Inc. (SERA) Q2 2026 Earnings Call Transcript

August 12, 2026 | seekingalpha.com

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

August 12, 2026 | aol.comA

Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Misses Revenue Estimates

August 12, 2026 | zacks.com

Sera Prognostics (NASDAQ:SERA) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

August 12, 2026 | marketbeat.com

Sera Prognostics (SERA) Projected to Post Quarterly Earnings on Wednesday

August 11, 2026 | americanbankingnews.com

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026

July 29, 2026 | prnewswire.com

Sera Prognostics (SERA) Expected to Announce Earnings on Wednesday

July 29, 2026 | marketbeat.com

PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE

July 9, 2026 | prnewswire.com

SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS

June 30, 2026 | prnewswire.com

SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTH

June 24, 2026 | prnewswire.com

SERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY

June 23, 2026 | prnewswire.com

All You Need to Know About Sera Prognostics (SERA) Rating Upgrade to Buy

June 19, 2026 | zacks.com

Sera Prognostics (NASDAQ:SERA) CFO Sells $11,315.20 in Stock

June 11, 2026 | insidertrades.com

Sera Prognostics Holds 2026 Annual Stockholders Meeting

June 4, 2026 | tipranks.com

SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION

June 1, 2026 | prnewswire.com

Sera Prognostics (SERA) Loses 27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

May 14, 2026 | zacks.com

Sera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2026 Financial Results

May 9, 2026 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLR, GANX, RLYB, and SERA Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

$1.37 +0.01 (+0.74%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.38 +0.01 (+0.73%)

As of 08/14/2026 07:57 PM Eastern

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Gain Therapeutics NASDAQ:GANX

$2.12 -0.04 (-1.85%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$2.14 +0.02 (+0.94%)

As of 08/14/2026 07:38 PM Eastern

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

Rallybio NASDAQ:RLYB

$16.99 +0.03 (+0.18%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$16.98 0.00 (-0.03%)

As of 08/14/2026 07:41 PM Eastern

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Sera Prognostics NASDAQ:SERA

$1.96 -0.05 (-2.49%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.96 +0.01 (+0.26%)

As of 08/14/2026 07:57 PM Eastern

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALLR, GANX, RLYB, and SERA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALLR, GANX, RLYB, and SERA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALLR, GANX, RLYB, and SERA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLR, GANX, RLYB, and SERA Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

Gain Therapeutics NASDAQ:GANX

Rallybio NASDAQ:RLYB

Sera Prognostics NASDAQ:SERA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALLR, GANX, RLYB, and SERA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALLR, GANX, RLYB, and SERA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALLR, GANX, RLYB, and SERA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLR, GANX, RLYB, and SERA Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

Gain Therapeutics NASDAQ:GANX

Rallybio NASDAQ:RLYB

Sera Prognostics NASDAQ:SERA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools